Innovative Eyewear (NASDAQ:LUCY – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Profitability
This table compares Innovative Eyewear and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Innovative Eyewear | -225.26% | -88.90% | -80.34% |
| TriSalus Life Sciences | -62.59% | N/A | -64.47% |
Valuation and Earnings
This table compares Innovative Eyewear and TriSalus Life Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Innovative Eyewear | $2.66 million | 2.91 | -$7.59 million | ($1.29) | -0.69 |
| TriSalus Life Sciences | $45.15 million | 5.97 | -$39.23 million | ($1.30) | -3.37 |
Innovative Eyewear has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for Innovative Eyewear and TriSalus Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Innovative Eyewear | 1 | 1 | 0 | 0 | 1.50 |
| TriSalus Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
TriSalus Life Sciences has a consensus target price of $10.20, suggesting a potential upside of 132.88%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than Innovative Eyewear.
Volatility and Risk
Innovative Eyewear has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
Summary
TriSalus Life Sciences beats Innovative Eyewear on 10 of the 14 factors compared between the two stocks.
About Innovative Eyewear
Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Innovative Eyewear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovative Eyewear and related companies with MarketBeat.com's FREE daily email newsletter.
